Revision as of 20:26, 4 November 2022 editEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers170,767 edits +sd← Previous edit | Revision as of 05:45, 27 December 2024 edit undoD6dmso (talk | contribs)33 editsNo edit summaryTag: Visual editNext edit → | ||
Line 45: | Line 45: | ||
}} | }} | ||
'''Rociverine''' is an ] drug.<ref name="pmid582702">{{cite journal | vauthors = Toson G, Schiantarelli P, Murmann W | title = Rociverine, a new antispasmodic agent with balanced neurotropic and myotropic activity | journal = Arzneimittel-Forschung | volume = 28 | issue = 7 | pages = 1130–42 | date = 1978 | pmid = 582702 | doi = | url = }}</ref> | '''Rociverine''' is an antispasmodic drug used to treat urinary, gastrointestinal and biliary spasms.<ref>{{Cite web |title=Rociverine |url=https://go.drugbank.com/drugs/DB13581}}</ref> It is ] drug.<ref name="pmid582702">{{cite journal | vauthors = Toson G, Schiantarelli P, Murmann W | title = Rociverine, a new antispasmodic agent with balanced neurotropic and myotropic activity | journal = Arzneimittel-Forschung | volume = 28 | issue = 7 | pages = 1130–42 | date = 1978 | pmid = 582702 | doi = | url = }}</ref> | ||
The (1R,2R) compound showed 240-fold greater affinity for the muscarinic receptor, but the (1S,2S) compound showed the best selectivity. <ref>{{Cite journal |last=Barbier |first=Pascaline |last2=Renzetti |first2=Anna R. |last3=Turbanti |first3=Luigi |last4=Di Bugno |first4=Cristina |last5=Fornai |first5=Francesco |last6=Vaglini |first6=Francesca |last7=Maggio |first7=Roberto |last8=Corsini |first8=Giovanni U. |date=1995-07 |title=Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine |url=https://linkinghub.elsevier.com/retrieve/pii/0922410695900241 |journal=European Journal of Pharmacology: Molecular Pharmacology |language=en |volume=290 |issue=2 |pages=125–132 |doi=10.1016/0922-4106(95)90024-1}}</ref> | |||
==References== | ==References== |
Revision as of 05:45, 27 December 2024
Chemical compoundThis article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Clinical data | |
---|---|
Other names | (1S)-1-(diethylamino)propan-2-yl 1-hydroxybi(cyclohexane)-2-carboxylate |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.356 |
Chemical and physical data | |
Formula | C20H37NO3 |
Molar mass | 339.520 g·mol |
(verify) |
Rociverine is an antispasmodic drug used to treat urinary, gastrointestinal and biliary spasms. It is antimuscarinic drug.
The (1R,2R) compound showed 240-fold greater affinity for the muscarinic receptor, but the (1S,2S) compound showed the best selectivity.
References
- "Rociverine".
- Toson G, Schiantarelli P, Murmann W (1978). "Rociverine, a new antispasmodic agent with balanced neurotropic and myotropic activity". Arzneimittel-Forschung. 28 (7): 1130–42. PMID 582702.
- Barbier, Pascaline; Renzetti, Anna R.; Turbanti, Luigi; Di Bugno, Cristina; Fornai, Francesco; Vaglini, Francesca; Maggio, Roberto; Corsini, Giovanni U. (1995-07). "Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine". European Journal of Pharmacology: Molecular Pharmacology. 290 (2): 125–132. doi:10.1016/0922-4106(95)90024-1.
{{cite journal}}
: Check date values in:|date=
(help)
Drugs for functional gastrointestinal disorders (A03) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drugs for functional bowel disorders |
| ||||||||||||
Belladonna and derivatives (antimuscarinics) |
| ||||||||||||
Propulsives |
This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it. |